

Supplementary Table S2. Characteristics of uveal melanoma metastatic tumors under systematic therapy

Patient	Tissue collected	Treatment Naïve or S/P treatment	Anatomic location	Prior Treatment	Category
1	3/12/2013	Treatment Naïve	liver		
	5/22/2013	Treatment Naïve	skin scalp		
	9/18/2013	S/P treatment	skin chest	Ipilimumab 10 mg/kg	IMMUNOTHERAPY
2	3/13/2013	Treatment Naïve	liver		
	4/4/2013	Treatment Naïve	liver		
	1/29/2014	S/P treatment	left flank soft tissue	Ipilimumab 10 mg/kg	IMMUNOTHERAPY
	4/4/2014	S/P treatment	liver	intratumoral autologous dendritic cell vaccine	IMMUNOTHERAPY
3	10/24/2014	Treatment Naïve	liver		
4	6/7/2013	Treatment Naïve	liver		
5	7/3/2012	Treatment Naïve	liver		
6	6/20/2014	Treatment Naïve	liver		
	6/26/2014	Treatment Naïve	liver		
	5/27/2015	S/P treatment	liver	Ipilimumab 3 mg/kg + Temozolomide	IMMUNOTHERAPY
7	7/11/2014	Treatment Naïve	liver		
8	9/5/2014	Treatment Naïve	liver		
9	9/10/2014	Treatment Naïve	liver		
10	11/5/2014	Treatment Naïve	liver		
11	11/13/2014	Treatment Naïve	liver		

12	11/18/2014	Treatment Naïve	liver		
13	4/18/2014	Treatment Naïve	liver		
14	7/29/2014	Treatment Naïve	liver		
15	7/3/2014	Treatment Naïve	liver		
16	7/29/2013	Treatment Naïve	liver		
17	2/6/2013	Treatment Naïve	lung		
	3/19/2013	Treatment Naïve	lung		
	6/25/2014	S/P treatment	soft tissue	Mekinist and Yttrium-90 radioembolization	LIVER DIRECTED THERAPY
	6/29/2014	S/P treatment	epidural soft tissue	Mekinist and Yttrium-90 radioembolization	LIVER DIRECTED THERAPY
18	12/14/2011	Treatment Naïve	lung		
	1/24/2012	Treatment Naïve	lung		
	5/30/2014	Treatment Naïve	lung		
19	3/24/2014	Treatment Naïve	lung		
20	4/12/2013	Treatment Naïve	soft tissue		
	1/13/2014	S/P treatment	abdomen	arginine deaminase plus cisplatin	ANTIMETABOLITE AND CHEMOTHERAPY
	6/5/2014	S/P treatment	abdomen	crizotinib	TARGETED THERAPY
	9/10/2014	S/P treatment	abdomen	crizotinib plus trametinib	TARGETED THERAPY
21	10/7/2014	Treatment Naïve	soft tissue		
22	4/4/2014	Treatment Naïve	soft tissue		
	6/6/2014	S/P treatment	Subcutaneous	trametinib	TARGETED THERAPY
	11/17/2014	S/P treatment	Subcutaneous	trametinib plus AKT inhibitor	TARGETED THERAPY
	12/1/2014	S/P treatment	Subcutaneous	valproic acid	EPIGENETIC THERAPY
23	6/4/2014	Treatment Naïve	scalp connective		

			tissue		
	3/12/2015	S/P treatment	skeletal tissue	trametinib plus AKT inhibitor	TARGETED THERAPY
24	1/14/2014	S/P treatment	liver	anti-PD-L1 (MEDI-4736)	IMMUNOTHERAPY
25	9/5/2014	S/P treatment	liver	Ipilimumab 10 mg/kg	IMMUNOTHERAPY
26	1/8/2014	S/P treatment	liver	Ipilimumab 10 mg/kg	IMMUNOTHERAPY
27	11/2/2015	S/P treatment	liver	microRNA	EPIGENETIC THERAPY
28	9/3/2014	S/P treatment	lung	vorinostat	EPIGENETIC THERAPY
	10/13/2014	S/P treatment	lung	vorinostat	EPIGENETIC THERAPY
29	1/24/2013	S/P treatment	per-hilar lymph node	liver-directed therapy (bland embolization)	LIVER DIRECTED THERAPY
	1/24/2013	S/P treatment	skin/ Subcutaneous	liver-directed therapy (bland embolization)	LIVER DIRECTED THERAPY
30	5/5/2015	S/P treatment	soft tissue	trametinib plus AKT inhibitor	TARGETED THERAPY
31	7/28/2014	Treatment Naïve			
	5/5/2015	S/P treatment	Lung	trametinib	TARGETED THERAPY